Glad to see more and more players are jumping into the stem cell therapy

[Farooqji]

A Phase 1/2a clinical trial evaluating TED-A9, a human stem cell-based therapy, in people with Parkinson’s disease has finished dosing with no safety concerns identified to date.

Embryonic stem cell transplant showing safety in 12 patients

The therapy, delivered as a cell transplant directly into the brain, was given successfully to 12 adults diagnosed with Parkinson’s five or more years ago and with evident disease motor symptoms, according to its developer, S.Biomedics.

It is intended to directly address Parkinson’s underlying mechanisms by replacing the dopamine-producing nerve cells progressively lost to patients with precursor cells able to grow into healthy dopaminergic neurons.

sbiomedics.com/eng/products...

parkinsonsnewstoday.com/new...

[jeffreyn]

"The trial is expected to finish in February 2026."

[Gallowglass]

thank you ! Would you know if there are any therapies based on adult stem cells?

[gomelgo in reply to Gallowglass]

Hope biosciences is currently recruiting. They are using fetal cells in the trials, but will be using your own cells after the trial and they use infusion instead of directly into the brain. Less invasive. At least this is how I understand it.

[gomelgo in reply to Gallowglass]

I have a request that studies involving animal models posted here would please come with a warning. It's painful to read them and I don't believe they are worth paying attention to. We simply do not have the same condition. Our pd was not induced by mptp or some other substance. And our brains and systems are not exactly the same as those of rats or monkeys or mice. I just wish the torture would stop because it's not only detrimental to them, it prolongs our agony as well by wasting time and money on investigations that don't result in accurate findings.

[Racerk]

Good news for us, thanks for sharing

[Farooqji]

Updated Status:

S.BIOMEDICS revealed promising one-year post-transplant data from their Phase 1/2a clinical trial of the TED-A9 cell therapy for Parkinson's disease. The data demonstrate efficacy profile of TED-A9 in 6 participants in the trial’s low and high dosing cohorts in a one-year follow-up.

Utilizing the Hoehn and Yahr scale which is a key parameter for assessing the severity of motor symptoms in Parkinson’s disease, 3 low-dose recipients demonstrated an average improvement of 19.4% (from stage 3.7 to 3.0), while 3 high-dose patients experienced a more significant improvement of 44.4% (from stage 3.7 to 2.0), indicating a notable shift from severe to milder disease states.

The trial is expected to finish in February 2026.

businesswire.com/news/home/...